share_log

Cantor Fitzgerald Reiterates Overweight on Jasper Therapeutics, Maintains $6 Price Target

Benzinga ·  Oct 12, 2023 11:50

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Jasper Therapeutics (NASDAQ:JSPR) with a Overweight and maintains $6 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment